| Cancer-related molecular mechanisms research | Lifetime | 41 | AU 3 | 99.71 |
| MicroRNA in disease regulation | Lifetime | 55 | AU 1 | 99.68 |
| Ferroptosis and cancer prognosis | Lifetime | 26 | AU 1 | 99.45 |
| Extracellular vesicles in disease | Lifetime | 51 | AU 2 | 99.25 |
| Circular RNAs in diseases | Lifetime | 68 | AU 1 | 99.28 |
| RNA modifications and cancer | Lifetime | 325 | AU 3 | 99.25 |
| Cancer, Hypoxia, and Metabolism | Lifetime | 284 | AU 9 | 99.15 |
| Autophagy in Disease and Therapy | Lifetime | 121 | AU 3 | 99.11 |
| Glioma Diagnosis and Treatment | Lifetime | 324 | AU 4 | 98.93 |
| Immune cells in cancer | Lifetime | 281 | AU 9 | 98.38 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 539 | AU 23 | 98.79 |
| Cancer Cells and Metastasis | Lifetime | 359 | AU 6 | 98.40 |
| Epigenetics and DNA Methylation | Lifetime | 886 | AU 19 | 98.05 |
| Nanoplatforms for cancer theranostics | Lifetime | 666 | AU 10 | 97.78 |
| Ubiquitin and proteasome pathways | Lifetime | 619 | AU 11 | 97.39 |
| interferon and immune responses | Lifetime | 653 | AU 24 | 96.21 |
| Signaling Pathways in Disease | Lifetime | 385 | AU 4 | 96.06 |
| Cancer Research and Treatments | Lifetime | 965 | AU 22 | 95.85 |
| Endoplasmic Reticulum Stress and Disease | Lifetime | 891 | AU 17 | 95.00 |
| Phagocytosis and Immune Regulation | Lifetime | 379 | AU 16 | 94.29 |
| Inflammatory Biomarkers in Disease Prognosis | Lifetime | 529 | AU 5 | 91.96 |
| Inflammation biomarkers and pathways | Lifetime | 570 | AU 4 | 76.81 |
| Macrophage Migration Inhibitory Factor | Lifetime | 987 | AU 42 | 79.53 |
| Cancer-related molecular mechanisms research | 2021-2025 | 18 | AU 1 | 99.78 |
| RNA modifications and cancer | 2021-2025 | 24 | AU 1 | 99.69 |
| Epigenetics and DNA Methylation | 2021-2025 | 32 | AU 1 | 98.81 |
| Autophagy in Disease and Therapy | 2021-2025 | 13 | AU 1 | 98.82 |
| Ferroptosis and cancer prognosis | 2021-2025 | 29 | AU 1 | 99.43 |
| interferon and immune responses | 2021-2025 | 12 | AU 1 | 98.51 |
| Immune cells in cancer | 2021-2025 | 31 | AU 1 | 98.87 |
| MicroRNA in disease regulation | 2021-2025 | 41 | AU 1 | 99.35 |
| RNA Research and Splicing | 2021-2025 | 60 | AU 1 | 97.73 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 223 | AU 8 | 99.13 |
| Extracellular vesicles in disease | 2021-2025 | 102 | AU 6 | 97.69 |
| Cancer, Hypoxia, and Metabolism | 2021-2025 | 100 | AU 3 | 96.97 |
| Ubiquitin and proteasome pathways | 2021-2025 | 90 | AU 2 | 95.33 |
| Circular RNAs in diseases | 2021-2025 | 185 | AU 2 | 95.79 |
| Lung Cancer Treatments and Mutations | 2021-2025 | 459 | AU 7 | 97.11 |
| Cytokine Signaling Pathways and Interactions | 2021-2025 | 66 | AU 3 | 92.40 |
| Nanoplatforms for cancer theranostics | 2021-2025 | 557 | AU 7 | 96.63 |
| Cancer, Lipids, and Metabolism | 2021-2025 | 265 | AU 15 | 92.88 |
| Glioma Diagnosis and Treatment | 2021-2025 | 673 | AU 12 | 94.57 |
| Immune Cell Function and Interaction | 2021-2025 | 933 | AU 27 | 91.38 |
| Histone Deacetylase Inhibitors Research | 2021-2025 | 188 | AU 2 | 90.95 |
| Cancer-related Molecular Pathways | 2021-2025 | 226 | AU 8 | 89.36 |
| Cancer Research and Treatments | 2021-2025 | 325 | AU 4 | 88.35 |
| Cancer Cells and Metastasis | 2021-2025 | 718 | AU 24 | 86.33 |
| Immune Response and Inflammation | 2021-2025 | 378 | AU 5 | 85.31 |
| Inflammasome and immune disorders | 2021-2025 | 548 | AU 11 | 87.12 |
| Genetic factors in colorectal cancer | 2021-2025 | 825 | AU 24 | 87.69 |
| Neuroblastoma Research and Treatments | 2021-2025 | 597 | AU 19 | 86.85 |
| TGF-β signaling in diseases | 2021-2025 | 47 | AU 2 | 82.68 |
| Brain Metastases and Treatment | 2021-2025 | 806 | AU 14 | 83.85 |
| Endoplasmic Reticulum Stress and Disease | 2021-2025 | 515 | AU 6 | 80.19 |
| Phagocytosis and Immune Regulation | 2021-2025 | 342 | AU 7 | 78.42 |
| Cardiac tumors and thrombi | 2021-2025 | 437 | AU 3 | 78.66 |
| Atherosclerosis and Cardiovascular Diseases | 2021-2025 | 858 | AU 24 | 76.28 |
| Inflammatory mediators and NSAID effects | 2021-2025 | 395 | AU 20 | 73.05 |
| PI3K/AKT/mTOR signaling in cancer | 2021-2025 | 455 | AU 7 | 71.71 |
| Biosimilars and Bioanalytical Methods | 2021-2025 | 948 | AU 9 | 72.79 |
| Vascular Tumors and Angiosarcomas | 2021-2025 | 474 | AU 6 | 68.38 |
| Macrophage Migration Inhibitory Factor | 2021-2025 | 174 | AU 2 | 65.15 |
| Microtubule and mitosis dynamics | 2021-2025 | 980 | AU 14 | 64.78 |
| Testicular diseases and treatments | 2021-2025 | 812 | AU 18 | 62.44 |
| Protease and Inhibitor Mechanisms | 2021-2025 | 665 | AU 10 | 62.33 |
| Advanced Glycation End Products research | 2021-2025 | 931 | AU 19 | 58.26 |
| Proteoglycans and glycosaminoglycans research | 2021-2025 | 809 | AU 18 | 53.55 |
| Protein Tyrosine Phosphatases | 2021-2025 | 641 | AU 8 | 48.11 |
| 14-3-3 protein interactions | 2021-2025 | 196 | AU 2 | 40.91 |
